Efficacy and Safety of Testosterone Nasal Gel for Treating Hypogonadism in Men.

Hypogonadism Clinical Trial

Official title:

A Randomized, Parallel, Double-dummy, Multi-center Phase III Study for Evaluation of Efficacy and Safety of Nasotestt Compared to Androgel Treating Hypogonadism in Male Research Participants.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03281187
• Other study ID #: TESFBM0717NA-III
• Status: Not yet recruiting
• Phase: Phase 3
• First received: September 11, 2017
• Last updated: September 18, 2017
• Start date: July 16, 2018
• Est. completion date: January 13, 2020

Study information

• Verified date: September 2017
• Source: FBM Industria Brasileira Ltda
• Contact: Maxuel Monteiro, Regulatory
• Phone: +55(62)3333-3500
• Email: maxuel.monteiro[@]fbmfarma.com.br
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase III study for evaluation of Nasotestt efficacy compared to Androgel in the treatment of male participants with hypogonadism condition (reduced levels of testosterone) that have clinical indication of hormonal replacement with testosterone.

Description:

This efficacy and safety study will evaluate the superiority of Nasotestt (nasal gel) treatment compared to Androgel (topic gel) after 60 days of starting use. The efficacy endpoint will be verified through the percentage of participants which presented at the end of 60 days normalized levels of total testosterone (<300 ng/dL to >1050 ng/dL). Secondary efficacy endpoints will be collected throughout the study through: evaluation of symptoms of erectile dysfunction (The International Index of Erectile Function - IIEF), symptoms of prostatic disease (International Prostate Symptom Score - IPSS), measurement of abdominal perimeter and clinical global response to treatment (CGI-I questionnaire). As exploratory investigation, the satisfaction/comfort of Nasotestt use will be assessed by a specific questionnaire that will be applied to participants at the end of study. Safety evaluation data will include report of all adverse events, including type, frequency, intensity, seriousness, severity and action taken related to the investigational product of the study.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 228
• Est. completion date: January 13, 2020
• Est. primary completion date: November 12, 2018
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male research participant, aged 18 years or older, with BMI between 18.50 and 32.00 kg/m2;

2. To present symptomatic or asymptomatic hypogonadism and serum total morning testosterone levels = 300 ng / dL;

3. Laboratory evaluation of prostate specific antigen (PSA) levels within the normal range established by the laboratory or with non clinically significant changes (NCS) judged by the study Investigator;

4. Rhinoscopy and Glatzel mirror test normal or with changes that do not interfere with nasal absorption of medication Test;

5. Present healthy skin in the region of Comparator product application (skin of the shoulder).

Exclusion Criteria:

1. Diagnostic of prostatic and/or breast neoplasia;

2. PSA levels 4 ng/mL or higher, or 3 ng/mL or higher with elevated risk for prostatic neoplasia development;

3. Treatment with estrogens, gonadotropin releasing hormone (GnRH), growth hormone (GH) in the last 12 months;

4. Treatment with testosterone or any other androgen in the last two weeks (oral, buccal and topic), four weeks (intramuscular) or twelve weeks (implant) that precede randomization in the study;

5. Active rhinitis: allergic, seasonal, medicinal, vasomotor and atrophic;

6. Presence of grade II or III septum deviation (in any region of the nasal septum) and / or presence of nasal polyps or other conditions that determine nasal obstruction;

7. Hypersensibility of testosterone as well as to components present in the formulation of drugs.

Related Conditions & MeSH terms

• Hypogonadism

Intervention

Drug:
• Nasotestt 5 mg
The 114 participants randomized to this arm must administer one packet of testosterone 5 mg nasal gel (Nasotestt) in each nostril 3 times a day for 60 days.
• Androgel 50 mg
The 114 participants randomized to this arm must administer one packet of testosterone 50 mg topic gel (Androgel) applied once daily to skin of shoulders for 60 days.

Other:
• Nasotestt Placebo
The participants randomized to this arm must administer one packet of placebo testosterone nasal gel (Nasotestt Placebo) in each nostril 3 times a day in addition to an active drug for 60 days.
• Androgel Placebo
The participants randomized to this arm must administer one packet of placebo testosterone topic gel (Androgel Placebo) applied once daily to skin of shoulders in addition to an active drug for 60 days.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
FBM Industria Brasileira Ltda	Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Satisfaction and comfort of Nasotestt use	Will be evaluated by specific questionnaire application at the end of study.	After 120 days
Primary	Superiority Efficacy of Nasotestt comparing to Androgel on normalization of the blood testosterone levels	The success of treatment will be evaluated through statistical comparison of percentage of participants that achieved normal blood testosterone levels after 60 days of use.	60 days
Secondary	Improvement of erectile dysfunction symptoms	Will be evaluated by statistical comparison between IIEF baseline values and results observed throughout study.	60 and 90 days after starting treatment.
Secondary	Improvement of prostatic symptoms	Will be evaluated by statistical comparison between I-PSS baseline values and results observed throughout study.	60 and 90 days after starting treatment.
Secondary	Improvement of abdominal perimeter	Will be evaluated by statistical comparison between baseline perimeter observed and other results obtained throughout study.	60 and 90 days after starting treatment.
Secondary	Global Clinical Response to treatment	Will be assessed by a CGI - I questionnaire applied at the end of study. This instrument evaluate the improvement observed by physician throughout the study compared to condition observed at the baseline visit.	90 days after starting treatment.
Secondary	Incidence of adverse events	Will be evaluated by periodic monitoring of adverse events, including changes in clinical laboratory parameters and vital signs occurred throughout the study.	During 120 days